Stem cells are also effective when administered intramuscularly
At the Bio International Convention held on June 18-21 in Boston, the Israeli company Pluristem Therapeutics announced promising results of a preclinical study devoted to evaluating the effectiveness of intramuscular administration of the cellular drug Placental eXpanded (PLX) developed by it.
Traditionally, to achieve a systemic effect, cellular drugs are administered by intravenous injections. However, the specialists of Pluristem Therapeutics have demonstrated that even with intramuscular administration, PLX has the desired therapeutic effect. Intramuscular administration in many respects wins over intravenous, as it is safer, less time-consuming and requires less financial costs, which can significantly expand the potential scope of the drug PLX.
A study on mice showed that intramuscular administration of PLX is safe, does not cause technical difficulties and is effective against a number of hematological diseases, as well as primary and secondary bone marrow insufficiency, including those developing with radiation sickness and as a complication of chemo and radiotherapy.
Intramuscular administration of PLX significantly increased the survival and recovery levels of bone marrow and peripheral blood cell populations in animals that had previously received a lethal dose of radioactive radiation. These results indicate that the tested method of administration of the drug provides stimulation of division and differentiation of hematopoietic stem cells (HSC) of the bone marrow into erythrocytes, leukocytes and platelets, which is of exceptional importance in the treatment of hematological diseases.
The success of the treatment of a 7-year-old girl with bone marrow aplasia who underwent two standard hematopoietic stem cell transplants from a related donor, which did not provide the proper result, is also important. The child's condition was stabilized by intramuscular injection of PLX. The results of the first application of this innovative procedure were published on May 9 this year on the website globes.co.il .
According to the director of Pluristem Therapeutics Liat Flaishon, the company's specialists are very pleased with the results obtained, which convincingly demonstrate the ability of the drug PLX to stimulate the activity of hematopoietic cells, and also refute the well-established idea that to obtain a systemic effect, a cellular drug must be administered intravenously.
The active ingredient of the drug PLX are adherent stromal cells isolated from the placenta, releasing a cocktail of therapeutic proteins when injected into the microenvironment created by various diseases accompanied by inflammation and ischemia.
Preparations based on Placental eXpanded have also been tested in humans: the results of phase I and II clinical trials indicate the safety and effectiveness of the first version of the drug PLX when administered locally for the treatment of end-stage peripheral artery diseases. In addition, Pluristem Therapeutics, together with United Therapeutics, is developing a number of drug modifications: PLX-PAD – for the treatment of myocardial ischemia, PLX-BMP – for the treatment of acute radiation sickness, bone marrow transplant failure and chemotherapy-induced bone marrow aplasia, and PLX–PAH - for the treatment of pulmonary hypertension. Preclinical animal studies have already demonstrated the potential efficacy of PLX in the treatment of other conditions accompanied by inflammation and ischemia, including diastolic heart failure, inflamed bowel syndrome, neuropathic pain and pulmonary fibrosis.
Evgeniya Ryabtseva
Portal "Eternal youth" http://vechnayamolodost.ru based on the materials of Pluristem Therapeutics: Pluristem Therapeutics' Cell Therapy Broadens Addressable Markets – Demonstrates Systematic Effectiveness of Intramuscular Delivery.
28.06.2012